RBCC Establishes New BioSciences Headquarters in Houston

NOKOMIS, Fla.--(BUSINESS WIRE)-- Rainbow Coral Corp. (OTCBB:RBCC) announced today that it has established the headquarters of its new biotechnology division—Rainbow BioSciences, LLC—in Houston, Texas, home of the world’s largest medical complex.

“We targeted Houston from the beginning due to its amazingly large and diverse medical research community based in the Texas Medical Center,” said RBCC CEO Patrick Brown. “The opportunities in Houston to develop new R&D partnerships and breakthroughs are unmatched anywhere else in the Southern U.S. We’re very excited to set up shop and forge ahead with our new biotech initiatives.”

With over $1.8 billion in annual academic research investments and over 160 life sciences companies, Houston attracts venture capitalists from across the nation to invest in the growing life sciences industry there.

“The city is the perfect incubator for a growing company like ours,” Brown said. “We look forward to developing new relationships with the researchers and investors who will help us develop the biotech solutions to a host of pressing wellness issues.”

For more information on Rainbow BioSciences’ biotechnology initiative, please visit www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Elan Corp. (NYSE: ELN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.



CONTACT:

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
[email protected]

KEYWORDS:   United States  North America  Florida  Texas

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical

MEDIA:

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.